LexDanaLexDanabeta
Inventor

Todd M. Heidelbaugh

Inventor
Fountain Valley, CA, US

Overview

59→
Patents
2005–2017
Patent span
Human necessities
Primary field (CPC A)

Patents· 59 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations39%
C07DHeterocyclic compounds38%
A61KPreparations for medical, dental or toiletry purposes17%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium5%
C07CAcyclic or carbocyclic compounds1%
PatentTitleYear
9,849,113Methods of treating a adrenergic mediated conditions20179,623,006'Methods of treating α adrenergic mediated conditions'20179,572,792'Coumarin compounds as receptor modulators with therapeutic utility'20179,073,888'Coumarin compounds as receptor modulators with therapeutic utility'20159,034,910'Methods of treating alpha adrenergic mediated conditions'20158,828,973'Compounds as receptor modulators with therapeutic utility'20148,815,923'Therapeutic compounds'20148,809,379'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20148,741,875'Compounds as receptor modulators with therapeutic utility'20148,735,399'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20148,735,438'Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors'20148,703,745'Compounds as receptor modulators with therapeutic utility'20148,703,746'Compounds as receptor modulators with therapeutic utility'20148,653,270'Compounds as receptor modulators with therapeutic utility'20148,653,062'Compounds as receptor modulators with therapeutic utility'20148,486,985'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20138,486,969'Therapeutic compounds'20138,440,644'Compounds as receptor modulators with therapeutic utility'20138,426,454'Therapeutic compounds'20138,383,646'Therapeutic ((bicylicheteroaryl)imidazolyl) methylheteroaryl compounds'20138,362,022'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20138,329,918'Selective alpha 2B/2C agonists'20128,258,167'Naphthylmethylimidizoles as therapeutic agents'20128,227,499'Substituted-aryl-(imidazole)-methyl)-phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors'20128,183,414'N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors'20128,178,571'Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same'20128,168,795'Selective sphingosine-1-phosphate receptor antagonists'20128,124,774'Therapeutic ((phenyl)imidazolyl)methylquinolinyl compounds'20128,119,807'Quinolynylmethylimidizoles as therapeutic agents'20128,071,636'Methods of treating alpha adrenergic mediated conditions'20118,071,635'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazole-2-ones and related compounds'20118,063,231'Methods of treating alpha adrenergic mediated conditions'20118,063,087'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazole-2-ones and, 4-(substituted cycloalkylmethyl) imidazole-2-ones and related compounds'20118,063,086'Imidazole-2-thiones'20118,049,037'Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof'20118,022,226'Nonsedating α-2 agonists'20118,013,169'Naphthylmethylimidizoles as therapeutic agents'20117,960,423'Imidazole-2-thiones'20117,943,641'7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline'20117,902,247'Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors'20117,868,020'Quinolynylmethylimidizoles as therapeutic agents'20117,838,545'4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists'20107,795,292'Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same'20107,683,089'4-(Phenylmethyl and substituted phenylmethyl)-imidazole-2-thiones acting as specific alpha2 adrenergic agonists'20107,569,584'4-(2-methyl-5,6,7,8-tetrahydro-quinolin-7-ylmethyl)-1,3-dihydro-imidazole-2-thione as specific alpha2b agonist and methods of using the same'20097,569,595'2-((2-thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronaphthalen-1(2H)-one'20097,419,994'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2- thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cyloalkenylmethyl) imidazol-2-ones and related compounds'20087,399,868'4-(Heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists'20087,396,849'4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as α2 adrenergic agonists'20087,390,829'Alpha-2 adrenergic agonists'20087,358,269'2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one'20087,345,077'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds'20087,323,485'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds'20087,323,477'7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline'20087,312,238'Nonsedating α-2 agonists'20077,276,522'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds'20077,141,597'Nonsedating α-2 agonists'20067,091,232'4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds'20066,841,684'Imidiazoles having reduced side effects'2005

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2005–2017Patents assigned to ALLERGAN INC (59)· patent assignee history
2005–2017Based in Fountain Valley, CA, US· patent location history
2011–2015Patents assigned to HEIDELBAUGH TODD M (24)· patent assignee history
2011–2015Patents assigned to CHOW KEN (22)· patent assignee history
2011–2015Patents assigned to NGUYEN PHONG X (20)· patent assignee history
2011–2015Patents assigned to SINHA SANTOSH C (14)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ALLERGAN INC592005–2017
HEIDELBAUGH TODD Mself242011–2015
CHOW KEN222011–2015
NGUYEN PHONG X202011–2015
SINHA SANTOSH C142011–2015
Locations
LocationPatentsSpan
Fountain Valley, California, US592005–2017